Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02354625 · ClinicalTrials.gov registry record · Phase 1
The Safety of ahSC in Chronic SCI With Rehabilitation
A Phase 1 study, sponsored by W. Dalton Dietrich.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT02354625 is a Phase 1 study that has completed, run by W. Dalton Dietrich. The registered enrollment target is 8 participants.
The verdict
NCT02354625, a Phase 1 study, has completed, sponsored by W. Dalton Dietrich.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) transplantation in participants with chronic SCI. This trial design is phase I, open label, unblinded, non-randomized, and non-placebo controlled multiple injury cohorts.
Interventions
- BIOLOGICAL Autologous human Schwann cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-01 |
| Est. Completion | 2019-08-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02354625
The ClinicalTrials.gov registry entry for NCT02354625 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is W. Dalton Dietrich, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Autologous human Schwann cells is the first listed.
NCT02354625 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02354625 about?
NCT02354625 is a clinical study titled "The Safety of ahSC in Chronic SCI With Rehabilitation". The purpose of this study is to assess the safety of autologous human Schwann cell (ahSC) transplantation in participants with chronic SCI. This trial design is phase I, open label, unblinded, non-randomized, and non-placebo controlled multiple injury cohorts.
What is the current status of trial NCT02354625?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2015-01. Estimated completion is 2019-08-12.
What interventions are being tested in trial NCT02354625?
The interventions under investigation include: Autologous human Schwann cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02354625?
This trial is sponsored by W. Dalton Dietrich, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.